Treatment of Castration-naive Metastatic Prostate Cancer

Zineb Hamilou; Giulia Baciarello; Karim Fizazi

doi:10.1016/j.euf.2018.02.004

Treatment of Castration-naive Metastatic Prostate Cancer

Zineb Hamilou, Giulia Baciarello, Karim Fizazi

Research output: Contribution to journal › Comment/debate

3 Citations (Scopus)

Abstract

Both docetaxel + androgen deprivation therapy (ADT) and abiraterone acetate 1000 mg/d + prednisone/prednisolone 5 mg/d + ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.

Original language	English
Pages (from-to)	518-521
Number of pages	4
Journal	European Urology Focus
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/j.euf.2018.02.004
Publication status	Published - 1 Dec 2017

Access to Document

10.1016/j.euf.2018.02.004

Cite this

@article{7795754048f445eeb1feec55e15dedd3,

title = "Treatment of Castration-naive Metastatic Prostate Cancer",

abstract = "Both docetaxel + androgen deprivation therapy (ADT) and abiraterone acetate 1000 mg/d + prednisone/prednisolone 5 mg/d + ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.",

author = "Zineb Hamilou and Giulia Baciarello and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2018 European Association of Urology",

year = "2017",

month = dec,

day = "1",

doi = "10.1016/j.euf.2018.02.004",

language = "English",

volume = "3",

pages = "518--521",

journal = "European Urology Focus",

issn = "2405-4569",

number = "6",

}

TY - JOUR

T1 - Treatment of Castration-naive Metastatic Prostate Cancer

AU - Hamilou, Zineb

AU - Baciarello, Giulia

AU - Fizazi, Karim

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Both docetaxel + androgen deprivation therapy (ADT) and abiraterone acetate 1000 mg/d + prednisone/prednisolone 5 mg/d + ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.

AB - Both docetaxel + androgen deprivation therapy (ADT) and abiraterone acetate 1000 mg/d + prednisone/prednisolone 5 mg/d + ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.

UR - http://www.scopus.com/inward/record.url?scp=85042495775&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2018.02.004

DO - 10.1016/j.euf.2018.02.004

M3 - Comment/debate

C2 - 29500136

AN - SCOPUS:85042495775

SN - 2405-4569

VL - 3

SP - 518

EP - 521

JO - European Urology Focus

JF - European Urology Focus

IS - 6

ER -

Treatment of Castration-naive Metastatic Prostate Cancer

Abstract

Access to Document

Other files and links

Cite this